Research programme: anti-interleukin-13 monoclonal antibody fragment - UCB PharmaAlternative Names: Anti-IL-13 Fab'
Latest Information Update: 16 Jul 2016
Price : $50 *
At a glance
- Originator UCB Pharma SA
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 13 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Belgium (Inhalation, Aerosol)
- 28 Sep 2011 Preclinical trials in Asthma in Belgium (Inhalation)